With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13104-56-8,4′-(4-Methoxyphenyl)-2,2′:6′,2”-terpyridine,as a common compound, the synthetic route is as follows.
General procedure: IrCl3 (0.0299g, 0.1mmol) was mixed with 3-MeO-Phtpy, 2-MeO-Phtpy or 4-MeO-Phtpy (0.0339g, 0.1mmol), 0.20mL DMSO and 0.50mL CH3OH in a Pyrex tube. The Pyrex tube containing the reaction mixture was then placed in liquid N2, vacuumed and sealed. The reaction was initiated by heating the reaction mixture to 80C. After two days of incubation at 80C, the resulting brown-black crystals were isolated and characterized by different spectroscopic and analytic techniques.
13104-56-8 4′-(4-Methoxyphenyl)-2,2′:6′,2”-terpyridine 630929, acatalyst-ligand compound, is more and more widely used in various.
Reference£º
Article; Qin, Qi-Pin; Meng, Ting; Tan, Ming-Xiong; Liu, Yan-Cheng; Luo, Xu-Jian; Zou, Bi-Qun; Liang, Hong; European Journal of Medicinal Chemistry; vol. 143; (2018); p. 1387 – 1395;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI